Literature DB >> 16878154

RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.

P A Bignone1, K Y Lee, Y Liu, G Emilion, J Finch, A E R Soosay, F M L Charnock, S Beck, I Dunham, A J Mungall, T S Ganesan.   

Abstract

We had previously defined by allele loss studies a minimal region at 6q27 (between D6S264 and D6S297) to contain a putative tumour suppressor gene. The p90 ribosomal S6 kinase-3 gene (p90 Rsk-3, RPS6KA2) maps in this interval. It is a serine-threonine kinase that signals downstream of the mitogen-activated protein kinase pathway. It is expressed in normal ovarian epithelium, whereas reduced or absent in tumours or cell lines. We show that RPS6KA2 is monoallelically expressed in the ovary suggesting that loss of a single expressed allele is sufficient to cause complete loss of expression in cancer cells. Further, we have identified two new isoforms of RPS6KA2 with an alternative start codon. Homozygous deletions were identified within the RPS6KA2 gene in two cell lines. Re-expression of RPS6KA2 in ovarian cancer cell lines suppressed colony formation. In UCI101 cells, the expression of RPS6KA2 reduced proliferation, caused G1 arrest, increased apoptosis, reduced levels of phosphorylated extracellular signal-regulated kinase and altered other cell cycle proteins. In contrast, small interfering RNA against RPS6KA2 showed the opposite effect in 41M cells. The above results suggest that RPS6KA2 is a putative tumour suppressor gene to explain allele loss at 6q27.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16878154     DOI: 10.1038/sj.onc.1209827

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

1.  Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer.

Authors:  Nada Milosevic; Benjamin Kühnemuth; Leonie Mühlberg; Stefanie Ripka; Heidi Griesmann; Carolin Lölkes; Malte Buchholz; Daniela Aust; Christian Pilarsky; Sebastian Krug; Thomas Gress; Patrick Michl
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  Two p90 ribosomal S6 kinase isoforms are involved in the regulation of mitotic and meiotic arrest in Artemia.

Authors:  Ru-Bing Duan; Li Zhang; Dian-Fu Chen; Fan Yang; Jin-Shu Yang; Wei-Jun Yang
Journal:  J Biol Chem       Date:  2014-04-22       Impact factor: 5.157

3.  RSK2 mediates NF-{kappa}B activity through the phosphorylation of IkappaBalpha in the TNF-R1 pathway.

Authors:  Cong Peng; Yong-Yeon Cho; Feng Zhu; Yan-Ming Xu; Weihong Wen; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  FASEB J       Date:  2010-04-12       Impact factor: 5.191

4.  Rsk-mediated phosphorylation and 14-3-3ɛ binding of Apaf-1 suppresses cytochrome c-induced apoptosis.

Authors:  Jiyeon Kim; Amanda B Parrish; Manabu Kurokawa; Kenkyo Matsuura; Christopher D Freel; Joshua L Andersen; Carrie E Johnson; Sally Kornbluth
Journal:  EMBO J       Date:  2012-01-13       Impact factor: 11.598

5.  Nightshift work, chronotype, and genome-wide DNA methylation in blood.

Authors:  Charleen D Adams; Kristina M Jordahl; Wade Copeland; Dana K Mirick; Xiaoling Song; Cassandra L Sather; Karl Kelsey; Andres Houseman; Scott Davis; Timothy Randolph; Parveen Bhatti
Journal:  Epigenetics       Date:  2017-11-27       Impact factor: 4.528

6.  RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation.

Authors:  Madhurima Saha; Audrey Carriere; Mujeeburahiman Cheerathodi; Xiaocui Zhang; Geneviève Lavoie; John Rush; Philippe P Roux; Bryan A Ballif
Journal:  Biochem J       Date:  2012-10-01       Impact factor: 3.857

7.  A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth.

Authors:  John C Schell; Kristofor A Olson; Lei Jiang; Amy J Hawkins; Jonathan G Van Vranken; Jianxin Xie; Robert A Egnatchik; Espen G Earl; Ralph J DeBerardinis; Jared Rutter
Journal:  Mol Cell       Date:  2014-10-21       Impact factor: 17.970

Review 8.  Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.

Authors:  Marie Cargnello; Philippe P Roux
Journal:  Microbiol Mol Biol Rev       Date:  2011-03       Impact factor: 11.056

9.  Kaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2.

Authors:  John Karijolich; Yang Zhao; Bret Peterson; Qiang Zhou; Britt Glaunsinger
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

10.  Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.

Authors:  Anna L Stratford; Christopher J Fry; Curtis Desilets; Alastair H Davies; Yong Y Cho; Yvonne Li; Zigang Dong; Isabelle M Berquin; Philippe P Roux; Sandra E Dunn
Journal:  Breast Cancer Res       Date:  2008-11-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.